4:48 PM
 | 
Sep 05, 2013
 |  BC Extra  |  Company News

G-BA rebuffs Lyxumia for Type II diabetes

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Type II diabetes drug Lyxumia lixisenatide from Sanofi (Euronext:SAN; NYSE:SNY) has "no additional benefit" over comparators. The...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >